Dr. Manikanda Arunachalam Tapped to Lead the Transformation of Life Sciences

Sep 28, 2017, 08:45 ET
GLENDALE, Calif., Sept. 28, 2017 /PRNewswire/ — Beyond Limits (BL), an artificial intelligence (AI) and cognitive computing company, today announced it has appointed Dr. Manikanda Arunachalam, Cardiologist and Venture Capital specialist, as its Senior Vice President for Corporate Development and Investments. Dr. Mani will lead Beyond Limits as it expands and adapts its technology for the healthcare and health tech space, bringing truly cognitive AI solutions to the sector via its Life Sciences platform.
Beyond Limits has appointed Dr. Manikanda Arunachalam, Cardiologist and Venture Capital specialist, as its Senior Vice President for Corporate Development and Investments
“Beyond Limits’ Life Sciences platform provides transformative value proposition to diverse stakeholders in the healthcare industry that could improve clinical outcomes, optimize costs and build sustainable business models,” said Dr. Mani. “Beyond Limits Life Sciences will be an ideal partner for health systems, care plans, CRO’s, genomics companies and many other providers in digital health and healthcare Internet of Things.”
Dr. Mani is a multi-disciplinary professional with expertise in venture capital and private equity, specializing in medical devices, genomics, digital health and healthcare IOT. He is a partner in DS Investments, where he focuses on healthcare technology investments. In addition, he serves on the board of HD Medical Group and is a Strategic Advisor to Guardant Health. Prior to joining Beyond Limits, Dr. Mani served on the Board of Directors at the KEF Company, overseeing its multi-million dollar healthcare investment portfolio. In addition, Dr. Mani has served in key strategic and management roles at Capricorn Healthcare and Special Opportunities Fund, Motherhood India, and Johnson & Johnson Medical Devices.
Dr. Mani began his career as a Cardiologist and was one of the pioneers in conducting multinational clinical trials through his work as an investigator for Eli Lilly, Servier, and Covance. He holds an MD from the prestigious Madras Medical College and an MBA in Finance and Strategy from the Wharton School of The University of Pennsylvania, where he also completed his Fellowship in Cardiology.
AJ Abdallat, CEO of Beyond Limits, said “Beyond Limits’ fast, agile, and cognitive AI technology is an ideal partner for the healthcare industry, where it can be adapted to numerous roles including patient care, data security, and automation of medical devices. With his combined strengths in business development and health technology, as well as strong clinical experience, Dr. Mani is the perfect person to lead our team as we expand into the healthcare space.”
Launched in 2014, Beyond Limits is a leader in AI and cognitive computing and was created to commercialize cutting edge IP developed by the team after over 20 years of success supporting NASA and the space program. With technologies proven in the unknown and extreme environment of space, Beyond Limits adapts and delivers AI software capable of tackling complex industrial and enterprise challenges with the benefits of mechanical automation and human-like reasoning. Beyond Limits recently announced a Series B investment with BP Ventures for $20 million.
About Beyond Limits
Beyond Limits is transforming proven space and defense technologies from NASA and the U.S. Department of Defense into innovative solutions to address large and emerging markets. These technologies were developed at Caltech/Jet Propulsion Laboratory (JPL) over the last two decades and were funded by NASA and the Department of Defense to address their complex and far-reaching problems. Beyond Limits leverages this existing R&D investment along with many of its own technologies to produce commercial products and solutions that are capable of addressing the emerging problems of AI today and beyond. For more information, please visit our website at www.beyond.ai.
Media Contact:
Edward M. Yang
Firecracker PR
1-888-317-4687 (ext. 702)
SOURCE Beyond Limits
Related Links